Ji J.A.,Late Stage Pharmaceutical and Processing Development |
Liu J.,Late Stage Pharmaceutical and Processing Development |
Shire S.J.,Late Stage Pharmaceutical and Processing Development |
Kamerzell T.J.,Late Stage Pharmaceutical and Processing Development |
And 4 more authors.
Pharmaceutical Research | Year: 2010
Purpose. To study recombinant human vascular endothelial growth factor (rhVEGF), the release characteristics from topical gel formulations, and its interaction with, the gelling agents. Methods. The release kinetics were followed by quantifying rhVEGF that diffused into the receptor chamber of Franz cells. Analytical ultracentrifuge (AUC) was used to characterize the sedimentation velocity of rhVEGF experienced in the gel. The interactions were characterized, by isothermal calorimetry (ITC), and rhVEGF conformation was assessed by circular dichroism (CD). Results. The fraction of protein released was linear with the square root of time. The release rate constants did. not show significant change within a wide range of bulk viscosities created by different concentrations of hydroxypropyl methylcellulose (HPMC) or MC gels. Sedimentation velocity determined by AUC generated comparable sedimentation coefficients of protein, in these gels. AUC and ITC revealed no significant interaction between. rhVEGF and HPMC and some change on secondary structure of the protein by Far UV CD, which was not the case with carboxymethyl cellulose (CMC). Conclusions. Microviscosity, not bulk viscosity, was the key factor for the release of rhVEGF from cellulosic gels such as HPMC. Interaction between rhVEGF and CMC resulted in slower, and reduced amount of, release from the gel. © 2010 Springer Science+Husiness Media, LLC. Source